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Abstract  29 
Curcumin health benefits are strongly limited by its poor aqueous solubility and low oral 30 
bioavailability. This work was focused on the development and characterization of solid lipid 31 
nanoparticles (SLNs) for the encapsulation of curcumin for oral administration. High shear 32 
homogenization and ultrasonication techniques were employed to prepare Compritol SLNs. 33 
The physicochemical characterization of round shaped curcumin-loaded SLNs was carried out 34 
by monitoring particle size (lower than 300 nm), zeta potential (-33 mV), drug loading 35 
capacity (1.60%), drug entrapment efficiency (80%), TEM analysis and in vitro drug release. 36 
Stability (4ºC) was investigated over one month. Parallel Artificial Membrane Permeability 37 
Assay (PAMPA) showed a considerable increase of curcumin permeated when formulated as 38 
SLNs. A modified release profile suggested that curcumin molecules are solubilized into the 39 
solid lipid matrix. The developed SLNs were produced without the use of solvents and all 40 
excipients were GRAS ingredients; both technology and composition were suitable for food 41 
application. 42 
 43 
Keywords: curcumin, solid lipid nanoparticles, Parallel Artific al Permeability Assay, in vitro 44 



























1. Introduction 58 
Curcumin is a yellow-colored phenolic natural constituent derived from the rhizome of the 59 
spice herb Curcuma longa L., widely known as turmeric. It has a broad spectrum of bi logical 60 
activities, principally antioxidant (Sharma, Manoharlal, Puri, & Prasad, 2010; Selvam,  61 
Subramanian, Gayathri, & Angayarkanni, 1995; Ruby, Kuttan, Babu, Rajasekharan, & Kuttan 62 
1995) anti-inflammatory (Menon & Sudheer, 2007; Rao, Basu, & Siddiqui, 1982), 63 
antibacterial (Negi, Jayaprakasha, Jagan Mohan Rao, & Sakariah, 1999), antifungal (Sharma, 64 
1976). Its chemopreventive (Devasena, Rajasekaran, Gunasekaran, Viswanathan, & 65 
Venugopal, 2003; Park, 2010) activity has received considerable attention because curcumin 66 
influences multiple signaling pathways, modulating more than 30 different proteins, including 67 
thioredoxin reductase, cyclooxygenase-2 (COX-2), protein kinase C (PKC), 5-lipoxygenase, 68 
activated AMP-activated protein kinase (AMPK) and tubulin. Other molecular targets 69 
modulated by this substance included transcription factors, growth factors and their receptors, 70 
cytokines, enzymes, and genes regulating cell prolife ation and apoptosis (Aggarwal, Kumar,  71 
& Bharti, 2003; Shishodia, Singh, & Chaturvedi, 2007; Aggarwal, Kuiken, Michelle, Laxmi, 72 
Kuzhuvelil, & Bokyung, 2009).  73 
Curcumin shows a good safety profile, no studies in either animals or humans have 74 
demonstrated any toxicity associated with its use, even at high doses (Shankar, Shantha, 75 
Ramesh, Murthy, & Murthy, 1980; Lao, Ruffin, Normolle, Heath, & Bailey, 2006). This safe 76 
profile has been reflected by the continuous increase of preparations based on curcumin 77 
marketed as food ingredient or constituent of dietary supplements. Despite multiple health 78 
benefits, its utility is strongly limited by its poor aqueous solubility and low oral 79 
bioavailability. The latter is attributed to poor absorption, extensive intestinal and hepatic 80 
metabolism, rapid elimination and clearance from the body (Pan, Huang, & Lin, 1999; Anand, 81 
Kunnumakkara, Newman, & Aggarwal, 2007). Formulation of curcumin in effective dosage 82 
forms represented a challenge to overcome its poor hysicochemical properties. Several 83 
strategies such as nanoparticles, liposomes, solid dispersions, microemulsions and 84 
complexation with phospholipids and cyclodextrins have been developed to improve the 85 
bioavailability of curcumin (Bisht, Feldmann, Soni, Ravi, Karikar, Maitra, & Maitra, 2007; 86 
Maiti, Mukherjee, Gantait, Saha, & Mukherjee, 2007; Tiyaboonchai, Tungpradit, & 87 
Plianbangchang, 2007; Sanoj Rejinold, Sreerekha, Chennazhi, Nair, & Jayakumar, 2011; 88 
Bergonzi, Hamdouch, Mazzacuva, Isacchi, & Bilia, 2014; Chaurasia, Patel, Chaubey,  Kumar, 89 















This study was focused on the preparation and charaterization of solid lipid nanoparticles 91 
(SLNs) for oral administration of curcumin (Dhillon, Aggarwal, Newman, Wolff,  92 
Kunnumakkara, & Abbruzzese, 2008). Lipid-based drug delivery systems are promising 93 
formulations, since lipids are known oral drug absorpti n enhancers (Porter, Wasan, & 94 
Constantinides, 2008; Chakraborty, Shukla, Mishra, & Singh, 2009) and they can be 95 
developed in small particle sizes ranging from micro to nanometers (Jia, 2005; Pouton, 2006), 96 
that can increase the absorption in the hydrophilic environment of the gastrointestinal tract. 97 
SLNs combine these features: they are colloidal carriers of submicron size constituted of solid 98 
lipids at body and room temperatures. Substances usd to prepare these nanoparticles are 99 
physiologic and generally recognized as safe compounds (GRAS ingredients); this aspect 100 
makes SLNs carriers without toxicity in humans (Müller, Mehnert, Lucks, Schwarz, Zur 101 
mühlen, & Meyhers, 1995). Moreover, they retain theadvantages of traditional colloidal 102 
systems (Müller, Mader, & Gohla, 2000) such as enhanced physical stability, protection of 103 
drug molecules from degradation in the body, controlled drug release, organ or tissue specific 104 
targeting, biocompatibility, laboratory to industrial-scalability. SLNs, consist of a lipid core 105 
and an outer shell of amphiphilic surfactant. If drug is loaded in the outer shell and on the 106 
particle surface, it is quickly released, displaying a burst effect. On the other hand, if it is 107 
incorporated into the particle core, it is released in a prolonged way. This make possible a 108 
controlled drug release from these carriers, represnting an important tool to obtain a 109 
prolonged release of the drug (Müller et al., 2000; Reddy, 2005).  110 
A few studies concerning the development of curcumin SLNs have been reported in the 111 
literature, but only one paper is dealing SLN for oral administration (Kakkar, Singh, Singla, & 112 
Kaur, 2011). This study described the preparation of SLNs using Tween 80, soy lecithin and 113 
Compritol with microemulsion technique. In vivo pharmacokinetics performed in rats after 114 
oral administration of SLNs revealed significant improvement of curcumin bioavailability, 115 
but the percentage of Tween 80 in the SLNs is quite high (more than six times higher than the 116 
lipid phase). In other studies, the percentage of surfactant is the same or much higher than that 117 
of the lipid (Kakkar, Mishra, Chuttani, & Kaur, 2013; Aditya, Macedo, Doktorovova, Souto, 118 
Kim, Chang, & Ko, 2014; Hazzah, Farid, Nasra, EL-Massik, & Abdallah, 2015; Sun, Bi, 119 
Chan, Sun, Zhang & Zheng, 2013).  120 
In the present study, the preparation of curcumin SLNs for a suitable oral dosage form was 121 
investigated, by using 50 g/kg fat phase and a low c ntent of surfactant (25 g/kg), very 122 















In addition, the development of SLNs was carried out by homogenization-ultrasonication 124 
technique without the use of the solvents, technology that can be applied also to an indusial 125 
process.  126 
Another key aspect was the analyses by DSC and X-ray diffractometry to investigate the 127 
drug-lipid interactions and the crystallinity of both curcumin and lipids, because this aspect 128 
could influence the release. Particle size analysis is a necessary, but not a sufficient step to 129 
characterize SLN quality. Special attention must be paid to the characterization of the degree 130 
of lipid crystallinity and the modification of the lipid, because these parameters are strongly 131 
correlated with drug incorporation and release profiles. DSC uses the fact that different lipid 132 
modifications possess different melting points and melting enthalpies. By means of X-ray 133 
scattering it is possible to assess the length of te long and short spacings of the lipid lattice.  134 
Finally, stability test, release profile and permeability assay were performed to confirm the 135 
optimized biopharmaceutical properties of the develop d nanovectors. The results confirmed 136 
that the developed SLNs offer a promising delivery system for enhancing the oral absorption 137 
of curcumin, suitable either for food fortification r as dietary supplements. 138 
  139 
2. Materials and methods 140 
2.1 Materials 141 
Compritol 888 ATO, a mixture of mono-, di- and triglycerides of behenic acid (C22), was a 142 
gift of Gattefossè (Milan, Italy). Curcumin, Pluronic F68 and 1,7-octadiene were purchased 143 
from Sigma Aldrich Corporation (St. Louis, MO, USA). Lecithin was kindly provided by 144 
Galeno (Comeana, Prato, Italy). Lipase from porcine pancreas, pepsin from porcine gastric 145 
mucose, bile salts and cholesterol were analytical gr de from Sigma Aldrich (Milan, Italy). 146 
96-well MultiScreen PAMPA filter plate were purchased from Millipore Corporation, 147 
(Tullagreen, Carrigtwohill, County Cork, Ireland). All the solvents used were HPLC grade 148 
from Merck (Darmstadt, Germany); 85% formic acid was provided by Carlo Erba (Milan, 149 
Italy). Ethanol analytical reagent grade was from Riedel-de Haen Laborchemikalien GmbH & 150 
Co. KG, (Seelze, Germany). Water was purified by a Milli-Q plus system from Millipore 151 
(Milford, MA). Phosphotungstic acid (PTA) was from Electron Microscopy Sciences 152 
(Hatfield, USA). Hydrion Buffer chemvelope pH 7.40±0.02 was purchased from Micro 153 


















2.2 High shear homogenization-ultrasonication method 158 
Blank and drug loaded SLNs were prepared using hot homogenization process followed by 159 
ultrasonication (Castelli et al., 2005). Two formulations were investigated (SLN-1 and SLN-160 
2) loaded with two different concentrations of curcumin: 0.01 g/g and 0.02 g/g respect to the 161 
lipid phase, respectively. 162 
Briefly, different amounts of curcumin, (respectively 75 and 150 mg) were accurately 163 
weighed and added to melted Compritol (7.5 g, 80ºC). Pluronic F68 (3.75 g) was dissolved in 164 
distilled water (138 g) and heated at 85ºC in a beaker. When a clear homogenous lipid phase 165 
was obtained, hot aqueous surfactant solution was added to hot lipid phase and homogenized 166 
at 9660 x g, by using a high-speed stirrer (Ultra Turrax T25, IKA-Werke GmbH&Co. KG, 167 
Staufen, Germany) for five minutes. The temperature was maintained at 80ºC during this step. 168 
Then, the coarse emulsion was subjected to probe sonication (Sonopuls HD 2200, 200 W 169 
power, probe MS 72, Bandelin Electronic GmbH, Berlin, Germany) for different times. Probe 170 
sonication process was suspended for 2’ intervals during each cycle, to prevent increase of 171 
temperature. Temperature was monitored during the process. Sonication was applied 172 
maximum for 15 minutes to avoid metal contamination, by considering also previously 173 
published experimental conditions (Silva, González-Mira, García, Egea, Fonseca, Silva, 174 
Santos, Souto, & Ferreira, 2011;  Müller, Rühl, Runge, Schulze-Forster, & Mehnert, 1997; 175 
Nassimi, Schleh, Lauenstein, Hussein, Hoymann, & Koch, 2010; Nayak, Tiyaboonchai, 176 
Patankar, Madhusudhan, & Souto, 2010; Vitorino, Carvalho, Almeida, Sousa, & Pais, 2011).  177 
Working temperature was kept at least 5ºC above the lipid melting point (85°C) to prevent 178 
recrystallization during homogenization and ultrasonication. After ultrasonication, the 179 
obtained emulsion (O/W) was cooled in an ice bath in order to solidify the lipid matrix and to 180 
form SLNs. Blank and curcumin loaded SLNs were prepa d and characterized as well. SLNs 181 
dispersions were stored at 4ºC for further analyses. 182 
 183 
2.3 Particle size analysis and zeta potential measurements 184 
Mean diameter of the population and polydispersity index (P.I.) as a measure of the width of 185 
particle size distribution together with the measure of zeta potential values were assessed by 186 
photon correlation spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern Instruments, 187 
UK). Samples were prepared diluting 10 µl of SLN suspension with 2 ml of deionized water. 188 















because it value could alter the zeta-potential. pH resulted 6.1 prior to dilution and 6.3 after 190 
dilution. 191 
2.4 Determination of encapsulation efficiency 192 
The percentage of curcumin entrapped in the lipid matrix was determined as follows: a fixed 193 
amount of SLNs dispersion was purified by dialysis method, using a membrane 194 
(MW=12.400, Sigma Aldrich, Milan, Italy). Then, an mount of material retained in the bag 195 
was freeze-dried at -40ºC for 24 h, for following stability studies. The freeze drying process 196 
was optimized to obtain a homogenous porous solid an  ccording to TEM and light 197 
scattering analyses. 198 
Sample was dissolved in MeOH under stirring at 80°C for 10 min and then cooled to room 199 
temperature to preferentially precipitate the lipid (Nayak, et al., 2010; Tiyaboonchai,  200 
Tungpradit, & Plianbangchang, 2007; Sanna, Gavini, Cossu, Rassu, & Giunchedi, 2007). The 201 
suspension was centrifuged for 30 minutes at 13148 x g and the supernatant was analyzed by 202 
HPLC/DAD analysis using curcumin as external standard. Calibration curves were performed 203 
on six solutions in the concentration range 1.38–13 µg/ml. The squared correlation 204 
coefficient was >0.99. Curcumin encapsulation efficien y was expressed as drug recovery and 205 




 The drug loading content was the ratio of incorporated drug to lipid (w/w): 210 
 211 
 212 
No lipid interference occurred during UV determinaton of curcumin (data not shown). 213 
Curcumin loaded concentration was assayed by HPLC/DAD analysis performed using a HP 214 
1100 Liquid Chromatograph (Agilent Technologies, Palo Alto, CA, USA) equipped with a 215 
HP 1040 Diode Array Detector (DAD), an automatic injector, an auto sampler and a column 216 
oven and managed by a HP 9000 workstation (Agilent Technologies, Palo Alto, CA, USA). 217 
The UV-Vis spectra were recorded between 220–500 nm a d the chromatographic profiles 218 
was registered at 420 nm. Separations were performed on a reversed phase column Luna C18 219 
(150 x 4.6 mm, 5 µm, Phenomenex) maintained at 27°C. The eluents wereH2O at pH 3.2 by 220 















min at a flow rate of 0.4 ml/min: 0.10 min 72% A and 18% of B; 10.0 min 56% A to 44% B; 222 
27.0 min 52% A to 48% B; 27.0 min 52% A to 48% B;  32.0 min 20% A to 80% B . 223 
2.5 Transmission electron microscopy (TEM) 224 
The morphological characterization of the systems was obtained by using transmission 225 
electron microscopy technique (TEM, CM12 Philips, Netherlands). Samples were deposited 226 
on a formuvar film-coated copper grid and then stained with one drop of 20 g/L aqueous 227 
solution of phosphotungstic acid (PTA), allowing to dry before TEM observation. 228 
 229 
2.6 Differential scanning calorimetry (DSC)  230 
DSC was carried out using a Mettler TA4000 apparatus equipped with a DSC 25 cell. 231 
Samples (about 10 mg) were accurately weighed (Mettler M3 Microbalance) directly in 232 
pierced aluminum pans and scanned between 30 and 250°C at a heating rate of 10 K min-1 233 
under static air. DSC thermograms of pure curcumin, Compritol, and curcumin-loaded SLNs 234 
were compared.   235 
2.7 X-ray powder diffractometry 236 
X-ray powder diffractograms were obtained with a Bruker D8 advance powder 237 
diffractometer, equipped with Cu Kα radiation and operating in ϑ-2ϑ Bragg Brentano 238 
geometry at 40 kV and 30 mA. The “SolX” solid-state d tector was used. C/Ni Goebel 239 
mirrors for the incident beam were used. The samples w re analyzed at ambient temperature 240 
over the 10–35° 2ϑ range at a scan rate of 0.02 deg s−1. 241 
2.8 In vitro release studies 242 
Dialysis bag method was applied to study the drug release using a mixture of PBS (pH 6.8) 243 
and EtOH (150 mL/L ethanol to maintain the sink conditions) or simulated intestinal fluid as 244 
dissolution media. Simulated intestinal conditions contained intestinal enzymes (lipase 0.4 245 
mg/ml, bile salts 0.7 mg/ml and pancreatin 0.5 mg/ml) and calcium chloride solution 750 mM 246 
at pH 7.0, (Aditya, et al., 2014). Release was monitored for 12 h. The dialysis bags were 247 
hydrated in PBS before use. Two milliliter of SLNs dispersion was introduced into the 248 
dialysis bag. The bag was placed in a beaker containi g 200 mL of dissolution medium 249 















were withdrawn at different time intervals and replaced with the same volume of fresh 251 
medium to maintain the sink conditions. The samples w re suitably diluted and analyzed for 252 
curcumin determination. All the operations were carried out in triplicate. 253 
2.9 Stability studies 254 
Stability of curcumin SLNs was studied over 1 month. SLNs were kept at 4±1°C and at fixed 255 
time intervals; they were assayed for their physical stability. Physical stability was checked by 256 
monitoring size, zeta potential and polydispersity of formulation. 257 
2.10 Parallel artificial membrane permeability assay (PAMPA) 258 
The PAMPA assay is a method for predicting passive int stinal absorption. The assay is 259 
carried out in a 96-well, MultiScreen-IP PAMPA (Millipore corporation) filter plate. The 260 
ability of compounds to diffuse from a donor compartment, through a PVDF membrane filter 261 
pretreated with a lipid-containing organic solvent, i o an acceptor compartment is evaluated. 262 
5 µL of lecithin (10g/L) and cholesterol (8g/L) in 1,7-octadiene solution were added to the 263 
filter of each well. Immediately after the application of the artificial membrane, 150 µL of 264 
drug containing donor solutions (free drug or curcumin-SLNs diluted in 0.05 mL/mL 265 
DMSO/PBS) were added to each well of the donor plate. In details, SLNs suspension was 266 
diluted to obtain in each donor compartment a final concentration of curcumin of 160 µg. A 267 
saturated solution of curcumin (0.3 µg of curcumin solubilized in the donor compartment) 268 
was used as control. 300 µL of buffer (0.05 mL/mL DMSO/PBS, pH 7.4) were adde to each 269 
well of the acceptor plate. The acceptor plate was then placed into the donor plate, ensuring 270 
that the underside of the membrane was in contact with buffer. The plate was covered and 271 
incubated at room temperature under shaking for 24 hours and permeation was evaluated at 1, 272 
2, 4, 6, 19, 24 hours.  273 
3. Results and Discussion 274 
3.1 Preparation of SLNs 275 
The use of solid lipids instead of liquid oils is a very attractive idea to achieve controlled drug 276 
release, because drug mobility in a solid lipid should be considerably lower, compared with a 277 
liquid oil. SLNs are non-toxic, high biocompatible and easy to produce in large scale. SLN 278 
are drug carriers composed of a solid core suitable to target drugs to specific intestine 279 















the particles are in the solid state. Therefore, th mobility of incorporated drugs is reduced, 281 
which is a prerequisite for controlled drug release. 282 
Selected SLNs consisting of a core of Compritol were stabilized with Pluronic F68. Compritol 283 
was selected because it is a mixture of mono, di an triglycerides. Moreover, Compritol in 284 
enhancing the oral bioavailability in comparison to other lipid matrices was previously 285 
highlighted (Paliwal, Rai, Vaidya, Khatri, Goyal, Mishra, Mehta, & Vyas, 2009). 286 
Compritol–based nanoparticles were heterogeneous with better drug-loading and release 287 
characteristics as compared with the other formulations. Accordingly, SLNs containing lipids 288 
with highly crystalline structure can give drug expulsion. On the other hand, the imperfections 289 
(lattice defects) of the lipid structure could offer more loading space to accommodate drugs 290 
(Westesen, Bunjes, & Koch, 1997; Muller et al., 2000; Silva, González-Mira, García, Egea, 291 
Fonseca, & Silva, 2011; Freitas & Müller, 1999; Mehn rt & Mäder, 2012) while the use of a 292 
mixture of different oils as lipophilic can benefit the encapsulation efficiency. Compritol was 293 
also chosen as the lipid component because it gives stable dispersions with smaller particles. 294 
Two formulations with different amount of curcumin (0.01 g/g and 0.02 g/g respect to the 295 
lipid phase, SLN-1 and SLN-2 respectively) were prepa d and fully characterized.  296 
Homogenization-ultrasonication method was selected b cause economical, efficient and 297 
reproducible process to produce SLNs. Effect of different process variables on size, P.I., zeta 298 
potential, encapsulation efficiency was analyzed, and the results were reported on Table 1. 299 
Homogenization time was maintained constant at 10 minutes, time necessary to obtain a good 300 
emulsification of lipid (Das, Ng, Kanaujia, Kim, & Tan, 2011).  301 
Sonication time (5, 10 and 15 minutes) showed huge influence on particle size. Sizes 302 
significantly decreased with increasing sonication time and the samples resulted always 303 
homogeneous. The best results in terms of P.I. values were found in the formulations SLN-1 304 
and SLN-2, when 15 minutes of sonication were applied.  305 
All formulations were negatively charged, the zeta potential varied from -10 to -45 mV 306 
indicating a relatively good stability and dispersion of the system. The negative value of zeta 307 
potential of SLNs was attributed to the presence of behenic acid into the lipid matrix surface 308 
and also to Pluronic. This is a non-ionic surfactant used in the production of relatively stable 309 
dispersions. Although non-ionic surfactant could not i teract with charging group like ionic 310 
ones, but it can influence the particle/water interface and electric double layer. Pluronic can 311 
also provide additional steric stabilization of particles (Schwarz & Mehnert, 1999; Lim & 312 















The quantity of curcumin loaded in the system increased the dimensions of SLNs: with 2% 314 
(0.02 g/g) the sizes ranged from 415 to 270, by increasing the sonication time. Particle size 315 
slightly increased with higher drug concentration; this is probably due to the presence of 316 
curcumin inside of lipidic core. 317 
The data in Table 1 shows that all formulations posses ed high entrapment efficiency (E.E. 318 
%) ranged from 70.7±2% to 80.2±2%. Encapsulation effici ncy was not significantly 319 
different among SLN-1 and SLN-2, resulting around of 70%; such values might be related to 320 
the structure of the lipid which had a great influenc  on drug incorporation. Lipids which 321 
form highly crystalline particles with a perfect structure lead to drug expulsion (Westesen et 322 
al., 1997), while, more complex lipids such as Compritol, being mixtures of mono-, di- and 323 
triglycerides, produce less perfect structures with many imperfections offering space to 324 
accommodate curcumin (Müller et al., 2000). Another feature of Compritol that favors the 325 
encapsulation of lipophilic curcumin was the high hydrophobicity due to the long chain fatty 326 
acids attached to the triglycerides.  327 
The formulation selected on the basis of the best properties in terms of size, P.I. and zeta 328 
potential was SLN-2-15, loaded with 0.02g/g of curcumin and sonicated for 15 minutes: it 329 
showed also an encapsulation efficiency of 80% and was selected for further investigations. 330 
 331 
3.2 TEM analysis 332 
TEM was conducted to investigate the morphology of solid lipid nanoparticles SLN-2-15. It 333 
was evident from TEM images that nanoparticles were almost spherical with smooth 334 
morphology, appeared as black dots, well dispersed and separated (Figure 1). This description 335 
agrees with a previous observation that the use of chemically heterogeneous lipids in 336 
combination with heterogeneous surfactants favors the formation of ideally spherical lipid 337 
nanoparticles (Mehnert & Mader, 2001). The mean diameter was in the range of 250-300 nm. 338 
3.3 DSC and X-ray diffractometry assay 339 
DSC and X-ray diffraction were performed for the assessment of the drug–lipid interactions 340 
and the crystallinity of curcumin and lipid matrices, because this aspect could influence the in 341 
vitro and in vivo release of the compound from the systems (Müller et al., 2000). Lipid 342 
crystallization is an important point for the performance of the SLN carriers. In fact, less 343 
perfect crystals with many imperfections can offer space to accommodate the drug (Müller et 344 















(Mehnert & Mäder, 2001; Silva et al., 2011; Mehnert & Mäder, 2012). The lack of 346 
crystallinity is also highly required to avoid extrusion of drug during storage. 347 
The following samples were analysed: pure curcumin, Compritol, unloaded and loaded SLNs 348 
SLN-2-15. Figure 2 depicts the DSC thermograms obtained. As Compritol is not composed of 349 
pure triacylglycerols, the observed melting peak at 72.1ºC might be due to a mixture of 350 
metastable polymorphic β and β' forms. The thermogram showed also a relatively small 351 
endothermic shoulder at around 55ºC; this small shoulder corresponds to the melting of a very 352 
unstable modification of Compritol which is the α modification (Souto et al., 2006), that 353 
clearly disappears after the nanoparticles preparation. DSC analysis of curcumin showed the 354 
melting point at 173.17ºC. In the DSC thermograms of blank SLNs (unloaded) and loaded 355 
SLNs, a small endothermic peak was observed at 50ºC. This peak indicates the presence of 356 
Pluronic either in the form of coating surrounding the nanoparticles or as residue after dialysis 357 
and lyophilization.  358 
Curcumin melting peak was not recorded in the SLN formulation attributed to the solubility 359 
of the drug within the solid lipid matrix. 360 
X-ray diffraction studies evidenced that diffraction pattern of bulk Compritol (Figure 3) 361 
presents two main typical signals at 21.5° (2θ) and 23.5° (2θ), significantly modified when 362 
formulated into nanoparticles. Besides, another signal arises at 19.4° (2θ) after SLN 363 
preparation, corresponding to the most stable polymrphic form of triacylglycerols β (Souto, 364 
Mehnert, & Müller, 2006). These results might indicate that the final formulation is composed 365 
of the most stable polymorphic state of Compritol: SLNs seem to lose part of their 366 
crystallinity by transforming from a mixture of β and β' polymorphs in the most stable β 367 
polymorph and allowing curcumin to penetrate in the molecular gaps.  368 
3.4 In vitro release studies 369 
The release of curcumin from SLN-2-15 formulation was tested in vitro in of PBS (pH 6.8) 370 
and simulated intestinal medium. Due to the poor aqueous solubility of curcumin, ethanol 371 
(150 mL/L) was used in the receptor medium to mimic sink condition, as already described in 372 
literature (Kakkar et al., 2011; Mulik, Mönkkönenc, Juvonend, Mahadika, & Paradkarb, 373 
2010). Cumulative drug release percentage versus time was plotted to demonstrate the release 374 
patterns (Figure 4). In both dissolution media a sustained/prolonged release. Curcumin 375 
reached about 40% of the amount loaded in the formulation during 12 hours in PBS. This may 376 
be attributed to the curcumin released slowly from the lipidic solid matrices, through diffusion 377 















release rate of SLNs could be influenced by complex factors, it was reported that among the 379 
factors, the large surface area and high diffusion c efficient due to small molecular size or 380 
low viscosity in the matrix are preponderant (zur Mühlen, Schwarz, & Mehnert, 1998).  381 
The release profile was similar, but more intense during the incubation of SLNs in simulated 382 
intestinal medium. After 12 h the percentage reached about 60%. The presence of enzymes 383 
and bile salts caused a pronounced release, probably due to degradation of the lipid carrier 384 
and the subsequent solubilization of curcumin in colloidal species, like mixed micelles and 385 
swollen micelles (Noack, Oidtmann, Kutza, & Mäder, 2012). 386 
 387 
3.5 Stability studies 388 
Stability of curcumin solid lipid nanoparticles was studied over 1 month. Physical stability 389 
was checked by monitoring size, zeta potential and P.I. during time, by DLS measurements. 390 
There was no modification neither of the particle size nor of the zeta potential (Figure 5). 391 
Furthermore, polydispersity was stable over time, no vesicle size alterations occurred over the 392 
tested period. 393 
 394 
 3.6 Parallel artificial membrane permeability assay (PAMPA) 395 
An approach for rapid assessment of absorption potential include the Parallel Artificial 396 
Membrane Permeability Assay (PAMPA) (Kansy, Avdeef, & Fischer, 2004). Pampa is based 397 
on a 96-well microplate technology and allows reason ble throughput, although it lacks 398 
similarity to natural membranes because it does not possess pores or active transport 399 
mechanism. It enables fast determination of the trends in the ability of the compounds to 400 
permeate membrane by passive diffusion and it is thu  suited for the screening of large 401 
libraries. Due to their small particle size, SLNs may exhibit bioadhesion properties to the 402 
gastrointestinal tract wall or enter in the intervillar spaces thus increasing their residence time 403 
in the gastrointestinal tract and releasing the active drug encapsulated. This increase in 404 
adhesion results in enhanced bioavailability. 405 
The experiment was carried out measuring the ability of curcumin to diffuse from our SLNs 406 
suspension to a donor compartment through a PVDF membrane.  407 
A showed a strong increase of permeated curcumin was found in the case of SLNs suspension 408 
when compared with a saturated solution of curcumin used as control (Figure 6). In the case 409 
of SLNs, 4.2 µg, 7.9 µg and 9.3 µg of curcumin permeated to the acceptor compartment after 410 















respectively of curcumin permeated from saturated solution. We can observe also that in the 412 
case of aqueous saturated solution, the amount of permeated curcumin remains constant 413 
during the test while, in the case of SLNs, permeated curcumin increases with time during 24 414 
h of test.  415 
 416 
4. Conclusions 417 
In this study the poorly-soluble curcumin was incorporated into SLNs by homogenization and 418 
ultrasound technique without the use of solvents.  419 
Compritol demonstrated good solubilization of curcumin and formulation was obtained in 420 
terms of drug loading, surfactant percentage and soication time. Pluronic F68 was selected 421 
as surfactant in the amount of 28 g/L of the formulation. SLN-2-15 formulation showed good 422 
values of encapsulation efficiency, size, P.I., zeta potential and stability. 423 
These SLNs resulted round shape with homogeneous size distribution, as confirmed by TEM 424 
analysis. Size of the particles is a key factor for improve oral performance of poorly soluble 425 
drugs and the average particle size of the developed nanoparticles was maintained below 300 426 
nm, like other effective formulations, such as microemulsions or submicron emulsions. The 427 
increased permeability of curcumin loaded in SLNs was confirmed by PAMPA, a simple 428 
technique to evaluate in vitro passive gastrointestinal performance of innovative carriers. A 429 
prolonged release profile was observed suggesting that curcumin is solubilized into the solid 430 
lipid matrix. An increase in saturation solubility and, consequently, an increase in the release 431 
rate of the drug allows it to reach high concentrations in the gastrointestinal tract. It is 432 
expected a better in vivo performance of SLN because Pluronic may increase the permeability 433 
through the intestinal membrane and they may promote the bioadhesion to the GI wall. Also, 434 
the incorporation of curcumin into SLNs solid lipid matrix reduces its enzymatic degradation 435 
during the process of absorption.  436 
SLNs are very versatile carriers, particularly for the oral administration, they can be easily 437 
transformed into powder (by spray-drying or lyophilization) and  converted into solid dosage 438 
forms, such as tablets, hard gelatin capsules, pellets or powders. The obtained powders can be 439 
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Figure 1: TEM micrographs of curcumin of SLN-2-15 sample (loaded with 0.02g/g of 
curcumin and obtained with 15 min of sonication) (Awith details of single SLN (B; C). 
Figure 2: DSC thermographs of Compritol; pure curcumin; blank and loaded solid lipid 
nanoparticles (SLN-2-15 sample, loaded with 0.02g/g of curcumin and obtained with 15 min 
of sonication). 
Figure 3: X-ray diffraction pattern of Compritol; pure curcumin; blank and loaded solid lipid 
nanoparticles SLN-2-15 sample, loaded with 0.02g/g of curcumin and obtained with 15 min 
of sonication). 
Figure 4: In vitro release profile of curcumin from SLN-2-15 sample (loaded with 0.02g/g of 
curcumin and obtained with 15 min of sonication). Each data represent the mean ± standard 
deviation of three experiments. 
Figure 5: Particle size (A), polydispersity index (P.I., B) and zeta potential (C) evolution of 
curcumin solid lipid nanoparticles (SLN-2-15 sample, loaded with 0.02g/g of curcumin and 
obtained with 15 min of sonication) at storage conditions (30 days, 4ºC). (Mean±S.D.; n=3). 
 
Figure 6: Permeation profile of free curcumin and curcumin loaded SLNs by Parallel 
artificial membrane permeability assay (PAMPA). Amount of curcumin is referred to each 
well. Black: control; grey: SLN-2-15 sample, loaded with 0.02g/g of curcumin and obtained 
























Table 1. Characterization of developed blank and curcumin loaded SLNs; effect of sonication 
time and amount of curcumin on size, polydispersity index (P.I.), encapsulation efficiency 
(EE%) and drug loading (D.L.%). SLN-1, SLN-2 are solid lipid nanoparticles loaded 
respectively with 0.01 and 0.02g/g of curcumin. 5, 10 and 15 indicate sonication time. Each 





















EE (%) DL (%) 
Blank SLN 5 - 333±1 0.28±0.02 -36±3 - - 
 10 - 254±6 0.25±0.01 -24±2 - - 
 15 - 241±9 0.33±0.03 -10±1 - - 
        
SLN-1-5 5 0.01 320±18 0.31±0.03 -45±2 76.4±4.9 0.76 
SLN-1-10 10 0.01 238±4 0.31±0.04 -34±4 74.2±16 0.74 
SLN-1-15 15 0.01 199±23 0.26±0.02 -39±4 76.4±4.6 0.76 
        
SLN-2-5 5 0.02 415±6 0.31±0.08 -39±3 70.7±2 1.41 
SLN-2-10 10 0.02 313±13 0.33±0.01 -29±4 77.8±8 1.56 
SLN-2-15 15 0.02 270±15 0.29±0.01 -33±3 80.2±2 1.60 




























































































































































1. Compritol and Pluronic were used to prepare curcumin oral solid lipid nanoparticles. 
2. Solid lipid nanoparticles resulted stable over 1 month at 4±1°C.  
3. In vitro studies showed a good release of curcumin from lipid nanoparticles. 
4. Formulation increases the amount of curcumin permeated by 2 orders of magnitude. 
 
 
